Cargando…

Application of Purified Botulinum Type A Neurotoxin to Treat Experimental Trigeminal Neuropathy in Rats and Patients with Urinary Incontinence and Prostatic Hyperplasia

Type A neurotoxin (NTX) of Clostridium botulinum was purified by a simple procedure using a lactose gel column. The toxicity of this purified toxin preparation was retained for at least 1 year at −30°C by supplementation with either 0.1% albumin or 0.05% albumin plus 1% trehalose. When purified NTX...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuka, Yoshizo, Yokoyama, Teruhiko, Yamamoto, Yumiko, Suzuki, Tomonori, Dwi Fatmawati, Ni Nengah, Nishikawa, Atsushi, Ohyama, Tohru, Watanabe, Toshihiro, Kuboki, Takuo, Nagai, Atsushi, Oguma, Keiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382382/
https://www.ncbi.nlm.nih.gov/pubmed/22745637
http://dx.doi.org/10.1155/2012/648384
_version_ 1782236490090151936
author Matsuka, Yoshizo
Yokoyama, Teruhiko
Yamamoto, Yumiko
Suzuki, Tomonori
Dwi Fatmawati, Ni Nengah
Nishikawa, Atsushi
Ohyama, Tohru
Watanabe, Toshihiro
Kuboki, Takuo
Nagai, Atsushi
Oguma, Keiji
author_facet Matsuka, Yoshizo
Yokoyama, Teruhiko
Yamamoto, Yumiko
Suzuki, Tomonori
Dwi Fatmawati, Ni Nengah
Nishikawa, Atsushi
Ohyama, Tohru
Watanabe, Toshihiro
Kuboki, Takuo
Nagai, Atsushi
Oguma, Keiji
author_sort Matsuka, Yoshizo
collection PubMed
description Type A neurotoxin (NTX) of Clostridium botulinum was purified by a simple procedure using a lactose gel column. The toxicity of this purified toxin preparation was retained for at least 1 year at −30°C by supplementation with either 0.1% albumin or 0.05% albumin plus 1% trehalose. When purified NTX was used to treat 49 patients with urinary incontinence caused by either refractory idiopathic or neurogenic detrusor overactivity, 36 patients showed significant improvement in symptoms. These beneficial effects were also observed in cases of prostatic hyperplasia. The results obtained with NTX were similar to that of Botox. The effects of NTX on trigeminal neuralgia induced by infraorbital nerve constriction (IoNC) in rats were also studied. Trigeminal ganglion neurons from ipsilateral to IoNC exhibited significantly faster onset of FM4-64 release than sham-operated contralateral neurons. Intradermal injection of NTX in the area of IoNC alleviated IoNC-induced pain behavior and reduced the exaggerated FM4-64 release in trigeminal ganglion neurons.
format Online
Article
Text
id pubmed-3382382
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-33823822012-06-28 Application of Purified Botulinum Type A Neurotoxin to Treat Experimental Trigeminal Neuropathy in Rats and Patients with Urinary Incontinence and Prostatic Hyperplasia Matsuka, Yoshizo Yokoyama, Teruhiko Yamamoto, Yumiko Suzuki, Tomonori Dwi Fatmawati, Ni Nengah Nishikawa, Atsushi Ohyama, Tohru Watanabe, Toshihiro Kuboki, Takuo Nagai, Atsushi Oguma, Keiji J Toxicol Clinical Study Type A neurotoxin (NTX) of Clostridium botulinum was purified by a simple procedure using a lactose gel column. The toxicity of this purified toxin preparation was retained for at least 1 year at −30°C by supplementation with either 0.1% albumin or 0.05% albumin plus 1% trehalose. When purified NTX was used to treat 49 patients with urinary incontinence caused by either refractory idiopathic or neurogenic detrusor overactivity, 36 patients showed significant improvement in symptoms. These beneficial effects were also observed in cases of prostatic hyperplasia. The results obtained with NTX were similar to that of Botox. The effects of NTX on trigeminal neuralgia induced by infraorbital nerve constriction (IoNC) in rats were also studied. Trigeminal ganglion neurons from ipsilateral to IoNC exhibited significantly faster onset of FM4-64 release than sham-operated contralateral neurons. Intradermal injection of NTX in the area of IoNC alleviated IoNC-induced pain behavior and reduced the exaggerated FM4-64 release in trigeminal ganglion neurons. Hindawi Publishing Corporation 2012 2012-06-14 /pmc/articles/PMC3382382/ /pubmed/22745637 http://dx.doi.org/10.1155/2012/648384 Text en Copyright © 2012 Yoshizo Matsuka et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Matsuka, Yoshizo
Yokoyama, Teruhiko
Yamamoto, Yumiko
Suzuki, Tomonori
Dwi Fatmawati, Ni Nengah
Nishikawa, Atsushi
Ohyama, Tohru
Watanabe, Toshihiro
Kuboki, Takuo
Nagai, Atsushi
Oguma, Keiji
Application of Purified Botulinum Type A Neurotoxin to Treat Experimental Trigeminal Neuropathy in Rats and Patients with Urinary Incontinence and Prostatic Hyperplasia
title Application of Purified Botulinum Type A Neurotoxin to Treat Experimental Trigeminal Neuropathy in Rats and Patients with Urinary Incontinence and Prostatic Hyperplasia
title_full Application of Purified Botulinum Type A Neurotoxin to Treat Experimental Trigeminal Neuropathy in Rats and Patients with Urinary Incontinence and Prostatic Hyperplasia
title_fullStr Application of Purified Botulinum Type A Neurotoxin to Treat Experimental Trigeminal Neuropathy in Rats and Patients with Urinary Incontinence and Prostatic Hyperplasia
title_full_unstemmed Application of Purified Botulinum Type A Neurotoxin to Treat Experimental Trigeminal Neuropathy in Rats and Patients with Urinary Incontinence and Prostatic Hyperplasia
title_short Application of Purified Botulinum Type A Neurotoxin to Treat Experimental Trigeminal Neuropathy in Rats and Patients with Urinary Incontinence and Prostatic Hyperplasia
title_sort application of purified botulinum type a neurotoxin to treat experimental trigeminal neuropathy in rats and patients with urinary incontinence and prostatic hyperplasia
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382382/
https://www.ncbi.nlm.nih.gov/pubmed/22745637
http://dx.doi.org/10.1155/2012/648384
work_keys_str_mv AT matsukayoshizo applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia
AT yokoyamateruhiko applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia
AT yamamotoyumiko applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia
AT suzukitomonori applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia
AT dwifatmawatininengah applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia
AT nishikawaatsushi applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia
AT ohyamatohru applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia
AT watanabetoshihiro applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia
AT kubokitakuo applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia
AT nagaiatsushi applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia
AT ogumakeiji applicationofpurifiedbotulinumtypeaneurotoxintotreatexperimentaltrigeminalneuropathyinratsandpatientswithurinaryincontinenceandprostatichyperplasia